Innate Pharma (IPHA) Receivables (2017 - 2025)

Innate Pharma (IPHA) has disclosed Receivables for 8 consecutive years, with $6.1 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Receivables fell 89.84% year-over-year to $6.1 million, compared with a TTM value of $6.1 million through Dec 2024, down 89.84%, and an annual FY2024 reading of $6.2 million, down 89.77% over the prior year.
  • Receivables was $6.1 million for Q4 2024 at Innate Pharma, down from $59.9 million in the prior quarter.
  • Across five years, Receivables topped out at $59.9 million in Q4 2023 and bottomed at $3.2 million in Q4 2022.
  • Average Receivables over 5 years is $23.6 million, with a median of $22.0 million recorded in 2021.
  • The sharpest move saw Receivables surged 1768.81% in 2023, then tumbled 89.84% in 2024.
  • Year by year, Receivables stood at $26.9 million in 2020, then dropped by 18.18% to $22.0 million in 2021, then crashed by 85.44% to $3.2 million in 2022, then soared by 1768.81% to $59.9 million in 2023, then crashed by 89.84% to $6.1 million in 2024.
  • Business Quant data shows Receivables for IPHA at $6.1 million in Q4 2024, $59.9 million in Q4 2023, and $3.2 million in Q4 2022.